为您找到相关结果约0个
你是不是要搜索 期刊CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) 点击跳转
为您找到相关结果约0个
暂无数据
为您找到相关结果约0个
你是不是要搜索 期刊CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) 点击跳转
为您找到相关结果约0个